 Christine Fisher
Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brachytherapy | 13 | 2023 | 103 | 4.370 |
Why?
| | Uterine Cervical Neoplasms | 13 | 2023 | 216 | 3.880 |
Why?
| | Endometrial Neoplasms | 8 | 2023 | 141 | 1.970 |
Why?
| | Breast Neoplasms | 19 | 2023 | 1862 | 1.810 |
Why?
| | Hysterectomy | 5 | 2019 | 106 | 1.800 |
Why?
| | Uterine Neoplasms | 5 | 2023 | 73 | 1.660 |
Why?
| | Carcinosarcoma | 3 | 2023 | 17 | 1.430 |
Why?
| | Databases, Factual | 5 | 2021 | 1124 | 1.120 |
Why?
| | Genital Neoplasms, Female | 3 | 2022 | 70 | 1.050 |
Why?
| | Radiation Oncology | 5 | 2022 | 75 | 1.050 |
Why?
| | Neoplasm Staging | 17 | 2021 | 1167 | 0.970 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 6 | 2023 | 117 | 0.940 |
Why?
| | Radiosurgery | 4 | 2023 | 299 | 0.900 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 3 | 2017 | 49 | 0.820 |
Why?
| | Chemoradiotherapy | 4 | 2019 | 188 | 0.810 |
Why?
| | Healthcare Disparities | 2 | 2018 | 479 | 0.790 |
Why?
| | Radiotherapy, Adjuvant | 6 | 2019 | 182 | 0.730 |
Why?
| | Simulation Training | 1 | 2021 | 61 | 0.720 |
Why?
| | Margins of Excision | 1 | 2019 | 29 | 0.640 |
Why?
| | Insurance, Health | 2 | 2018 | 244 | 0.640 |
Why?
| | Aquaporin 4 | 1 | 2019 | 87 | 0.620 |
Why?
| | Female | 51 | 2023 | 59461 | 0.610 |
Why?
| | Necrosis | 1 | 2019 | 211 | 0.610 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1355 | 0.570 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 152 | 0.560 |
Why?
| | Perioperative Care | 1 | 2018 | 127 | 0.560 |
Why?
| | Aged | 24 | 2023 | 19061 | 0.550 |
Why?
| | Middle Aged | 28 | 2023 | 26719 | 0.540 |
Why?
| | Insurance Coverage | 1 | 2018 | 200 | 0.540 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 29 | 0.540 |
Why?
| | Standard of Care | 1 | 2016 | 62 | 0.520 |
Why?
| | Neoplasms | 3 | 2022 | 2097 | 0.510 |
Why?
| | SEER Program | 6 | 2021 | 196 | 0.500 |
Why?
| | Survival Rate | 7 | 2019 | 1644 | 0.490 |
Why?
| | Neoplasm Recurrence, Local | 10 | 2021 | 858 | 0.490 |
Why?
| | Medical Errors | 1 | 2015 | 85 | 0.470 |
Why?
| | Health Plan Implementation | 1 | 2015 | 132 | 0.470 |
Why?
| | Adenocarcinoma | 3 | 2021 | 795 | 0.460 |
Why?
| | Humans | 56 | 2023 | 114616 | 0.460 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2014 | 76 | 0.450 |
Why?
| | Radiotherapy Dosage | 5 | 2023 | 244 | 0.450 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1141 | 0.440 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2023 | 445 | 0.440 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 311 | 0.430 |
Why?
| | Carcinoma | 1 | 2014 | 198 | 0.420 |
Why?
| | Pelvis | 1 | 2013 | 90 | 0.420 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1177 | 0.410 |
Why?
| | Internship and Residency | 1 | 2021 | 926 | 0.410 |
Why?
| | Combined Modality Therapy | 6 | 2020 | 1121 | 0.400 |
Why?
| | Receptor, ErbB-2 | 5 | 2021 | 300 | 0.390 |
Why?
| | Prostatectomy | 1 | 2012 | 98 | 0.390 |
Why?
| | United States | 13 | 2022 | 12176 | 0.360 |
Why?
| | Carcinoma, Endometrioid | 2 | 2023 | 46 | 0.360 |
Why?
| | Adult | 20 | 2023 | 30528 | 0.360 |
Why?
| | Mutation | 3 | 2023 | 3344 | 0.350 |
Why?
| | Mastectomy, Segmental | 4 | 2020 | 76 | 0.350 |
Why?
| | Lymphatic Metastasis | 3 | 2021 | 275 | 0.330 |
Why?
| | Re-Irradiation | 2 | 2020 | 8 | 0.320 |
Why?
| | Cancer Pain | 2 | 2018 | 20 | 0.300 |
Why?
| | Aged, 80 and over | 11 | 2023 | 6344 | 0.290 |
Why?
| | Treatment Outcome | 9 | 2023 | 9084 | 0.290 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 771 | 0.290 |
Why?
| | Prostatic Neoplasms | 2 | 2012 | 921 | 0.290 |
Why?
| | Sarcoma | 2 | 2021 | 137 | 0.280 |
Why?
| | Retrospective Studies | 13 | 2023 | 12542 | 0.270 |
Why?
| | Mastectomy | 3 | 2020 | 99 | 0.260 |
Why?
| | Neoadjuvant Therapy | 2 | 2018 | 304 | 0.250 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2021 | 332 | 0.250 |
Why?
| | Young Adult | 8 | 2021 | 10455 | 0.250 |
Why?
| | Prognosis | 6 | 2023 | 3328 | 0.240 |
Why?
| | Follow-Up Studies | 4 | 2018 | 4411 | 0.240 |
Why?
| | Papillomavirus Infections | 2 | 2019 | 261 | 0.240 |
Why?
| | Medical Oncology | 4 | 2019 | 229 | 0.230 |
Why?
| | Regression Analysis | 2 | 2019 | 944 | 0.230 |
Why?
| | Carcinoma, Renal Cell | 2 | 2015 | 168 | 0.220 |
Why?
| | Brain Neoplasms | 2 | 2023 | 979 | 0.220 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2023 | 14 | 0.210 |
Why?
| | Kaplan-Meier Estimate | 4 | 2021 | 811 | 0.210 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 126 | 0.210 |
Why?
| | Hodgkin Disease | 2 | 2016 | 120 | 0.210 |
Why?
| | Hydrocephalus | 1 | 2023 | 83 | 0.200 |
Why?
| | beta Catenin | 2 | 2023 | 219 | 0.190 |
Why?
| | Kidney Neoplasms | 2 | 2015 | 327 | 0.190 |
Why?
| | Veterans | 2 | 2022 | 1248 | 0.190 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 577 | 0.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 439 | 0.180 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 29 | 0.180 |
Why?
| | Benzodiazepines | 1 | 2021 | 116 | 0.170 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2021 | 157 | 0.160 |
Why?
| | Immunohistochemistry | 1 | 2023 | 1629 | 0.160 |
Why?
| | Lymph Nodes | 1 | 2021 | 419 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1394 | 0.160 |
Why?
| | Pain Management | 2 | 2018 | 288 | 0.150 |
Why?
| | Machine Learning | 1 | 2021 | 316 | 0.150 |
Why?
| | Adolescent | 5 | 2019 | 17830 | 0.150 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 1075 | 0.150 |
Why?
| | Relative Biological Effectiveness | 1 | 2017 | 3 | 0.140 |
Why?
| | Vulvar Neoplasms | 1 | 2017 | 10 | 0.140 |
Why?
| | Radiotherapy, Conformal | 1 | 2017 | 68 | 0.140 |
Why?
| | Antineoplastic Agents | 3 | 2017 | 1879 | 0.140 |
Why?
| | Propensity Score | 1 | 2018 | 224 | 0.140 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 67 | 0.130 |
Why?
| | Breast | 1 | 2017 | 139 | 0.130 |
Why?
| | Logistic Models | 2 | 2018 | 1840 | 0.130 |
Why?
| | Radiotherapy Setup Errors | 1 | 2015 | 3 | 0.130 |
Why?
| | Radiation Injuries | 1 | 2017 | 128 | 0.130 |
Why?
| | Curriculum | 1 | 2021 | 819 | 0.130 |
Why?
| | Neoplasm Grading | 4 | 2019 | 242 | 0.130 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 92 | 0.130 |
Why?
| | Risk Factors | 6 | 2020 | 8628 | 0.130 |
Why?
| | Physicians | 1 | 2023 | 772 | 0.130 |
Why?
| | Quality Control | 1 | 2015 | 144 | 0.120 |
Why?
| | Clinical Competence | 1 | 2021 | 893 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 201 | 0.120 |
Why?
| | Medically Uninsured | 1 | 2015 | 121 | 0.120 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 90 | 0.120 |
Why?
| | Checklist | 1 | 2015 | 83 | 0.120 |
Why?
| | Radiation Tolerance | 1 | 2015 | 92 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 718 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2019 | 3001 | 0.120 |
Why?
| | Cancer Vaccines | 2 | 2005 | 137 | 0.120 |
Why?
| | Internet | 1 | 2018 | 596 | 0.110 |
Why?
| | Breast Neoplasms, Male | 1 | 2013 | 28 | 0.110 |
Why?
| | Tumor Burden | 1 | 2014 | 259 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1214 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1518 | 0.110 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1077 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2017 | 490 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2015 | 194 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 442 | 0.110 |
Why?
| | Biomarkers, Tumor | 4 | 2023 | 1040 | 0.110 |
Why?
| | Patient Safety | 1 | 2015 | 277 | 0.100 |
Why?
| | Texas | 1 | 2012 | 188 | 0.100 |
Why?
| | Medicaid | 1 | 2015 | 406 | 0.100 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 31 | 0.100 |
Why?
| | DNA Polymerase II | 2 | 2023 | 37 | 0.100 |
Why?
| | Peptide Fragments | 2 | 2005 | 665 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2015 | 506 | 0.100 |
Why?
| | Male | 11 | 2022 | 55549 | 0.090 |
Why?
| | Registries | 1 | 2018 | 1767 | 0.090 |
Why?
| | Disease Management | 1 | 2014 | 560 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2177 | 0.090 |
Why?
| | Cohort Studies | 3 | 2021 | 4894 | 0.090 |
Why?
| | Age Factors | 1 | 2017 | 2894 | 0.090 |
Why?
| | Quality Indicators, Health Care | 2 | 2022 | 287 | 0.080 |
Why?
| | Melanoma | 1 | 2015 | 619 | 0.080 |
Why?
| | Survival Analysis | 1 | 2012 | 1211 | 0.080 |
Why?
| | Risk Assessment | 2 | 2020 | 2967 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2015 | 756 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3039 | 0.080 |
Why?
| | Opioid-Related Disorders | 3 | 2021 | 413 | 0.070 |
Why?
| | Epidemics | 2 | 2018 | 69 | 0.070 |
Why?
| | Fertility Preservation | 2 | 2019 | 46 | 0.070 |
Why?
| | Prospective Studies | 4 | 2023 | 6214 | 0.070 |
Why?
| | Prevalence | 1 | 2012 | 2249 | 0.070 |
Why?
| | Medicare | 2 | 2021 | 665 | 0.070 |
Why?
| | Gynecology | 2 | 2018 | 163 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 140 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2005 | 151 | 0.060 |
Why?
| | Radiotherapy | 2 | 2015 | 176 | 0.060 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 37 | 0.060 |
Why?
| | Information Seeking Behavior | 1 | 2023 | 35 | 0.050 |
Why?
| | Aromatase | 1 | 2023 | 30 | 0.050 |
Why?
| | Needles | 1 | 2023 | 49 | 0.050 |
Why?
| | Time Factors | 4 | 2020 | 6112 | 0.050 |
Why?
| | Receptors, Estrogen | 2 | 2016 | 372 | 0.050 |
Why?
| | Anthracyclines | 1 | 2021 | 41 | 0.050 |
Why?
| | Taxoids | 1 | 2021 | 93 | 0.050 |
Why?
| | Trastuzumab | 1 | 2021 | 89 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 45 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 172 | 0.040 |
Why?
| | Estrogens | 1 | 2023 | 312 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 537 | 0.040 |
Why?
| | Quinolines | 1 | 2021 | 129 | 0.040 |
Why?
| | Radiometry | 1 | 2019 | 42 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 32 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 40 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 76 | 0.040 |
Why?
| | Cervix Uteri | 1 | 2019 | 45 | 0.040 |
Why?
| | Organ Sparing Treatments | 1 | 2019 | 31 | 0.040 |
Why?
| | Papanicolaou Test | 1 | 2019 | 39 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2022 | 560 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 522 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 30 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 243 | 0.040 |
Why?
| | Papillomaviridae | 1 | 2019 | 101 | 0.040 |
Why?
| | India | 1 | 2018 | 134 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 140 | 0.040 |
Why?
| | Vagina | 1 | 2019 | 146 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 508 | 0.040 |
Why?
| | Organs at Risk | 1 | 2017 | 30 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1796 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 663 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 385 | 0.030 |
Why?
| | Skin Ulcer | 1 | 2015 | 13 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2015 | 26 | 0.030 |
Why?
| | HLA-A2 Antigen | 2 | 2005 | 36 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2015 | 32 | 0.030 |
Why?
| | Societies, Medical | 1 | 2019 | 663 | 0.030 |
Why?
| | Reoperation | 1 | 2017 | 514 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 453 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 268 | 0.030 |
Why?
| | Disease Progression | 2 | 2015 | 2380 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 953 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 124 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 668 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1036 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1018 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2013 | 305 | 0.030 |
Why?
| | Age Distribution | 1 | 2013 | 342 | 0.030 |
Why?
| | Sex Distribution | 1 | 2013 | 337 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 931 | 0.030 |
Why?
| | Skin | 1 | 2017 | 655 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1448 | 0.030 |
Why?
| | Mass Screening | 1 | 2019 | 1004 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 4620 | 0.020 |
Why?
| | Vinblastine | 1 | 2011 | 63 | 0.020 |
Why?
| | Receptors, Progesterone | 1 | 2013 | 319 | 0.020 |
Why?
| | Dacarbazine | 1 | 2011 | 99 | 0.020 |
Why?
| | Remission Induction | 1 | 2011 | 233 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4099 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1226 | 0.020 |
Why?
| | Doxorubicin | 1 | 2011 | 285 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1466 | 0.020 |
Why?
| | Bleomycin | 1 | 2011 | 228 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1715 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2084 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2311 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2279 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 43 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4405 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2005 | 195 | 0.020 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2005 | 154 | 0.020 |
Why?
| | Immunoconjugates | 1 | 2005 | 87 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2005 | 493 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2005 | 719 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2005 | 687 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 2710 | 0.010 |
Why?
| | Child | 1 | 2013 | 18402 | 0.010 |
Why?
|
|
Fisher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|